48 results on '"Balter R"'
Search Results
2. Current Diagnostic Possibilities for the Initial Forms of External Endometriosis
- Author
-
Blazhnova, E. M., primary, Oganesyan, A. T., additional, Ibrahimova, A. R., additional, Balter, R. B., additional, and Ivanova, T. V., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Patterns of clinical presentation of climacteric syndrome and total body composition in women with menopausal metabolic syndrome
- Author
-
Shulukian, Z. E., primary, Tselkovich, L. S., additional, Balter, R. B., additional, Ivanova, T. V., additional, Ibragimova, A. R., additional, Hamadianova, A. U., additional, and Ilchenko, O. A., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Human papillomavirus-associated cervical intraepithelial neoplasia in the presence of iodine deficiency
- Author
-
Sahautdinova, I. V., primary, Khamadianova, A. U., additional, Balter, R. B., additional, Ivanova, T. V., additional, and Ibragimova, A. R., additional
- Published
- 2021
- Full Text
- View/download PDF
5. EFFICACY OF PERSONALIZED THERAPY FOR PELVIC ORGAN PROLAPSE DEPENDING ON THE PRESENCE OF UNDIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA
- Author
-
Lysov, N. A., primary, Teleeva, G. I., additional, Tselkovich, L. S., additional, Ivanova, T. V., additional, Tyumina, O. V., additional, Rudenko, Yu. A., additional, Balter, R. B., additional, Ibragimova, A. R., additional, and Ilchenko, O. A., additional
- Published
- 2021
- Full Text
- View/download PDF
6. Features of the health status of women with genital prolapse
- Author
-
Teleeva, G. I., primary, Tselkovich, L. S., additional, Balter, R. B., additional, Ivanova, T. V., additional, Ibragimova, A. R., additional, and Ryabov, A. Yu., additional
- Published
- 2021
- Full Text
- View/download PDF
7. Evaluation of the effectiveness of electromyostimulation of pelvic floor muscles in combination with Kegel exercises on the state of genital prolapse in women
- Author
-
Teleeva, G. I., primary, Tselkovich, L. S., additional, Balter, R. B., additional, Ivanova, T. V., additional, Ibragimova, A. R., additional, Ilchenko, O. A., additional, and Pribytkov, D. L., additional
- Published
- 2020
- Full Text
- View/download PDF
8. Comparative evaluation of the effectiveness of immunomodulatory therapy for infectious mononucleosis of mixed etiology (Epstein Barr and cytomegalovirus) in children
- Author
-
Gasilina, E. S., primary, Frank, A. A., additional, Kitaychik, S. M., additional, Kabanova, N. P., additional, Buchina, G. A., additional, Bochkareva, N. M., additional, Borisova, O. V., additional, Polezhaeva, N. S., additional, Santalova, G. V., additional, Tselkovich, L. S., additional, and Balter, R. B., additional
- Published
- 2020
- Full Text
- View/download PDF
9. How to overcome a severe pulmonary aspergillosis in a patient with long-lasting aplasia after allogeneic haploidentical second transplant with unusual tools
- Author
-
Minniti, F, Mauro, M, Chinello, M, De Bortoli, M, Balter, R, Bonetti, E, Zaccaron, A, Vitale, V, Infante, M, Lo Cascio, G, and Cesaro, S.
- Subjects
Blackfan Diamond Anemia ,Aspergillosis ,Aspergillosis, Blackfan Diamond Anemia, Stem Cell Transplantation ,Stem Cell Transplantation - Published
- 2018
10. ALPS-lile phenothype due to ADA2 deficiency rescued by allogeneic stem cell transplantation
- Author
-
Barzaghi, F, Mauro, Margherita, Minniti, F, Chinello, M, De Bortoli, M, Balter, R, Bonetti, E, Zaccaron, A, Vitale, V, Brigida, I, Zoccolillo, M, Omrani, M, Degano, M, Cicalese, M. P., and Cesasro, S
- Subjects
Immunodeficiency ,Immunodeficiency, deficit of ADA2, stem cell transplantation ,deficit of ADA2 ,stem cell transplantation - Published
- 2018
11. Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up
- Author
-
Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, Gandola, L, Garrè, ML, Marras, CE, Buttarelli, FR, Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, Gandola, L, Garrè, ML, Marras, CE, and Buttarelli, FR
- Abstract
Purpose: The aims of patients’ radiological surveillance are to: ascertain relapse; apply second-line therapy; accrue patients in phase 1/2 protocols if second-line therapy is not standardized/curative; and assess/treat iatrogenic effects. To lessen the emotional and socioeconomic burdens for patients and families, we ideally need to establish whether scheduled radiological surveillance gives patients a better outcome than waiting for symptoms and signs to appear. Methods: We analyzed a prospective series of 160 newly-diagnosed and treated pediatric/adolescent patients with intracranial ependymoma, comparing patients with recurrent disease identified on scheduled MRI (the RECPT group; 34 cases) with those showing signs/symptoms of recurrent disease (the SYMPPT group; 16 cases). The median follow-up was 67 months. Results: No significant differences emerged between the two groups in terms of gender, age, tumor grade/site, shunting, residual disease, or type of relapse (local, distant, or concomitant). The time to relapse (median 19 months; range 5–104) and the MRI follow-up intervals did not differ between the SYMPPT and RECPT groups. The presence of signs/symptoms was an unfavorable factor for overall survival (OS) after recurrence (5-year OS: 8% vs. 37%, p = 0.001). On multivariable analysis, an adjusted model confirmed a significantly worse OS in the SYMPPT than in the RECPT patients. Conclusions: Symptomatic relapses carried a significantly worse survival for ependymoma patients than recurrences detected by MRI alone. It would therefore be desirable to identify recurrences before symptoms develop. Radiological follow-up should be retained in ependymoma patient surveillance because there is a chance of salvage treatment for relapses found on MRI
- Published
- 2018
12. Panipopituirarismo, sudorazione profusa e tumore: quale correlazione?
- Author
-
Neri, M., Coghi, A., Balter, R., Bonetti, E., Chinello, M., De Bortoli, M., Pegoraro, A., Vitale, VALENTINA ANGELA, Zaccaron, A., Davi, M. V., Camoglio, F. S., and Cesaro, S.
- Subjects
età pediatrica ,ipertensione ,feocromocitoma ,feocromocitoma, ipertensione, età pediatrica - Published
- 2017
13. Analisi di sopravvivenza ed esiti nei pazienti pediatrici con tumore cerebrale in età pediatirca trattati presso il centro di oncoematologia pediatrica di Verona dal 1999 al 2017
- Author
-
Coghi, A., Lorenzi, Maya, Tridello, G., De Bortoli, M., Panizzolo, I. S., Balter, R., Bonetti, E., Chinello, M., Pegoraro, A., Vitale, V., Zaccaron, A., Sala, F., Mazzarotto, Renzo, Pioli, Fabio, Ghimenton, C., and Cesaro, S.
- Subjects
pediatria ,tumori cerebrali, pediatria, medulloblastoma ,medulloblastoma ,tumori cerebrali - Published
- 2017
14. Uso della splenectomia nel trattamento della piastrinopenia allo-immune in pazienti trapiantati. XLI Annual Congress of AIEOP (Italian Association of Pediatric Hematology Oncology)
- Author
-
Mauro, M., Camoglio, F., Piccoli, P., De Bortoli, M., Balter, R., Pegoraro, A., and Cesaro, Simone
- Subjects
piastrinopenia, splenectomia, trapianto di cellule staminali emopoietiche ,piastrinopenia ,splenectomia ,trapianto di cellule staminali emopoietiche - Published
- 2016
15. L’anafilassi è un ostacolo insuperabile alla profilassi in un paziente con emofilia B
- Author
-
Mauro, M., Bonetti, E., Balter, R., Poli, G., and Cesaro, Simone
- Subjects
emofilia b ,emofilia b, inibitore, reazione anafilattica ,reazione anafilattica ,inibitore - Published
- 2016
16. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma
- Author
-
Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, Gandola, L., Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, and Gandola, L.
- Abstract
Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
- Published
- 2016
17. Study of hematologic and immunophenotypic features of Shwachman-Diamond syndrome
- Author
-
Mercuri, A, Cannata, E, Pervellini, O, Zampieri, F, Balter, R, Zaccaron, A, Zoppi, F, Tridello, G, Pizzolo, G, Krampera, Mauro, Cipolli, M, and Cesaro, Simone
- Subjects
bone marrow ,Shwachman-Diamond Disease ,Shwachman-Diamond Disease, immunophenotype, bone marrow ,immunophenotype - Published
- 2013
18. Study of hematologic and immunophenotypic features of Shwachman-Diamond sindrome patients
- Author
-
Mercuri, A, Cannata, E, Perbellini, O, Zampieri, F, Balter, R, Zaccaron, A, Zoppi, F, Tridello, G, Pizzolo, G, Crampera, M, Cipolli, M, and Cesaro, Simone
- Subjects
Shwachman-Diamond disease ,immunophotypic characteristic ,bone marrow transplant ,Shwachman-Diamond disease, immunophotypic characteristic, bone marrow transplant - Published
- 2013
19. Valutazione di cloni EPN mediante citometria a flusso ad elevata sensibilitàin pazienti affetti da anemia aplastica
- Author
-
Mercuri, A., Perbellini, O., Zampieri, F., Balter, R, Zaccaron, A, Cugno, C., Zoppi, F., and Cesaro, Simone
- Subjects
pediatric ,PNH ,cloni ,PNH, pediatric, cloni - Published
- 2012
20. Neuroblastoma metastatico MYCN non amplificato nell’infant: eccellente risultato con meno terapia
- Author
-
DI CATALDO, Andrea, Castellano, A, Garaventa, A, Viscardi, E, Bianchi, M, Luksch, R, Arcamone, G, Pession, A, Tettoni, K, Aru, B, Giuliano, M, Dangelo, P, Balter, R, Provenzi, M, Tamburini, A, Migliorati, R, Mastrangelo, S, Zanazzo, Ga, Bertuna, G, Nicolosi, A, Conte, M, and DE BERNARDI, B.
- Published
- 2008
21. Familial haemophagocytic lymphohistiocytosis: survival of a premature twin with immuno-chemotherapy and bone marrow transplantation from an HLA-identical unrelated donor
- Author
-
Padovani, Ezio Maria, Marradi, Pl, Balter, R, Maccario, R, Padovani, E., and Locatelli, F.
- Subjects
haemophagocytosis ,Farquhar's disease ,newborn ,haemophagocytosis, newborn, Farquhar's disease - Published
- 2005
22. Skeletal involvement in infants with neuroblastoma. A quality control study
- Author
-
Angelini, P, DE BERNARDI, B, Granata, C, Villavecchia, G, Prete, A, Tettoni, K, Aru, B, DI CATALDO, Andrea, Tamburini, A, Luksch, R, Giuliano, M, Viscardi, E, Dangelo, P, Castellano, A, Mastrangelo, S, Bianchi, M, Balter, R, and Castellani, R.
- Published
- 2005
23. Le coagulopatie congenite emorragiche
- Author
-
Gandini, G, Franchini, M, Lippi, Giuseppe, Zatti, M, Ddegani, D, Balter, R, Marradi, P, Tato', Luciano, and Aprili, G.
- Published
- 2001
24. EPENDYMOMA
- Author
-
Zaghloul, M., primary, Elbeltagy, M., additional, Mousa, A., additional, Eldebawy, E., additional, Amin, A., additional, Pavelka, Z., additional, Vranova, V., additional, Valaskova, I., additional, Tomasikova, L., additional, Oltova, A., additional, Ventruba, J., additional, Mackerle, Z., additional, Kren, L., additional, Skotakova, J., additional, Zitterbart, K., additional, Sterba, J., additional, Milde, T., additional, Kleber, S., additional, Korshunov, A., additional, Witt, H., additional, Hielscher, T., additional, Koch, P., additional, Koch, H.-G., additional, Jugold, M., additional, Deubzer, H. E., additional, Oehme, I., additional, Lodrini, M., additional, Grone, H.-J., additional, Benner, A., additional, Brustle, O., additional, Gilbertson, R. J., additional, von Deimling, A., additional, Kulozik, A. E., additional, Pfister, S. M., additional, Ana, M.-V., additional, Witt, O., additional, Kool, M., additional, Mack, S. C., additional, Taylor, M. D., additional, Fouyssac, F., additional, Schmitt, E., additional, Mansuy, L., additional, Marchal, J.-C., additional, Coffinet, L., additional, Bernier, V., additional, Chastagner, P., additional, Sperl, D., additional, Zacharoulis, S., additional, Massimino, M., additional, Schiavello, E., additional, Pizer, B., additional, Piette, C., additional, Kitanovski, L., additional, von Hoff, K., additional, Quehenberger, F., additional, Rutkowski, S., additional, Benesch, M., additional, Tzaridis, T.-D., additional, Bender, S., additional, Pfaff, E., additional, Barbus, S., additional, Bageritz, J., additional, Jones, D.-T.-W., additional, Kulozik, A., additional, Lichter, P., additional, Pfister, S.-M., additional, Song, S.-H., additional, Kang, C.-W., additional, Kim, S.-H., additional, Bandopadhayay, P., additional, Ullrich, N., additional, Goumnerova, L., additional, Scott, R. M., additional, Silvera, V. M., additional, Ligon, K. L., additional, Marcus, K. J., additional, Robison, N., additional, Manley, P. E., additional, Chi, S., additional, Kieran, M. W., additional, Biassoni, V., additional, Pierani, P., additional, Cesaro, S., additional, Maura, M., additional, Mack, S., additional, Jager, N., additional, Jones, D. T. W., additional, Stutz, A., additional, Northcott, P. A., additional, Fults, D. W., additional, Gupta, N., additional, Karajannis, M., additional, Rutka, J. T., additional, Korbel, J., additional, de Rezende, A. C. P., additional, Chen, M. J., additional, da Silva, N. S., additional, Cappellano, A., additional, Cavalheiro, S., additional, Weltman, E., additional, Currle, S., additional, Thiruvenkatam, R., additional, Murugesan, M., additional, Kranenburg, T., additional, Phoenix, T., additional, Gupta, K., additional, Gilbertson, R., additional, Rogers, H., additional, Kilday, J.-P., additional, Mayne, C., additional, Ward, J., additional, Adamowicz-Brice, M., additional, Schwalbe, E., additional, Clifford, S., additional, Coyle, B., additional, Grundy, R., additional, Mitra, B., additional, Domerg, C., additional, Andreiuolo, F., additional, Osteso-Ibanez, T., additional, Mauguen, A., additional, Varlet, P., additional, Le Deley, M.-C., additional, Lowe, J., additional, Ellison, D. W., additional, Grill, J., additional, Grundy, R. G., additional, Fleischhack, G., additional, Pajtler, K., additional, Zimmermann, M., additional, Warmuth-Metz, M., additional, Kortmann, R.-D., additional, Pietsch, T., additional, Faldum, A., additional, Bode, U., additional, Gandola, L., additional, Pecori, E., additional, Scarzello, G., additional, Barra, S., additional, Mascarin, M., additional, Scoccianti, S., additional, Mussano, A., additional, Garre, M. L., additional, Jacopo, S., additional, Viscardi, E., additional, Balter, R., additional, Bertin, D., additional, Giangaspero, F., additional, Pearlman, M., additional, Khatua, S., additional, Van Meter, T., additional, Koul, D., additional, Yung, A., additional, Paulino, A., additional, Su, J., additional, Dauser, R., additional, Whitehead, W., additional, Teh, B., additional, Chintagumpala, M., additional, Perek, D., additional, Drogosiewicz, M., additional, Filipek, I., additional, Polnik, M. P., additional, Baginska, B. D., additional, Wachowiak, J., additional, Kazmierczak, B., additional, Sobol, G., additional, Musiol, K., additional, Kowalczyk, J., additional, Slusarz, H. W., additional, Peregud-Pogorzelski, J., additional, Grajkowska, W., additional, Roszkowski, M., additional, Teo, W.-Y., additional, Okcu, F., additional, Mahajan, A., additional, Adesina, A., additional, Jea, A., additional, Bollo, R., additional, Paulino, A. C., additional, Velez-Char, N., additional, Doerner, E., additional, Muehlen, A. z., additional, Vladimirova, V., additional, Kortmann, R., additional, Friedrich, C., additional, von Bueren, A. O., additional, Barszczyk, M., additional, Buczkowicz, P., additional, Morrison, A., additional, Tabori, U., additional, Hawkins, C., additional, Krajewski, K., additional, Kammler, G., additional, von Bueren, A., additional, Krauss, J., additional, Ferreira, C., additional, Dieffenbach, G., additional, Barbosa, C., additional, Cuny, P., additional, Piccinin, E., additional, Brenca, M., additional, Lorenzetto, E., additional, Sardi, I., additional, Genitori, L., additional, Pollo, B., additional, Maestro, R., additional, Modena, P., additional, MacDonald, S., additional, Ebb, D., additional, Lavally, B., additional, Yeap, B., additional, Marcus, K., additional, Tarbell, N., additional, Yock, T., additional, Schittone, S., additional, Donson, A., additional, Birks, D., additional, Amani, V., additional, Griesinger, A., additional, Handler, M., additional, Madey, M., additional, Merchant, T., additional, Foreman, N., additional, Hukin, J., additional, Ailon, T., additional, Dunham, C., additional, Carret, A.-S., additional, McNeely, P. D., additional, Zelcer, S., additional, Wilson, B., additional, Lafay-Cousin, L., additional, Johnston, D., additional, Eisenstat, D., additional, Silva, M., additional, Jabado, N., additional, Yip, S., additional, Goddard, K., additional, Fryer, C., additional, Hendson, G., additional, Dunn, S., additional, Singhal, A., additional, Lassen-Ramshad, Y., additional, Vestergaard, A., additional, Seiersen, K., additional, Schultz, H. P., additional, Hoeyer, M., additional, Petersen, J. B., additional, Moreno, L., additional, Popov, S., additional, Jury, A., additional, Al Sarraj, S., additional, Jones, C., additional, Bowers, D., additional, Gargan, L., additional, Horton, C. J., additional, Rakheja, D., additional, Margraf, L., additional, Yeung, J., additional, Hamilton, R., additional, Okada, H., additional, Jakacki, R., additional, Pollack, I., additional, Fleming, A., additional, Saint-Martin, C., additional, Freeman, C., additional, Albrecht, S., additional, and Montes, J.-L., additional
- Published
- 2012
- Full Text
- View/download PDF
25. Recombinant human G-CSF-mobilized peripheral blood stem cells for second allogeneic transplant after bone marrow graft rejection in children
- Author
-
Zecca, M, Perotti, C, Marradi, P, Montagna, D, Giorgiani, G, Balter, R, Prete, L, Locatelli, Franco, Locatelli, F (ORCID:0000-0002-7976-3654), Zecca, M, Perotti, C, Marradi, P, Montagna, D, Giorgiani, G, Balter, R, Prete, L, Locatelli, Franco, and Locatelli, F (ORCID:0000-0002-7976-3654)
- Abstract
Two children affected by severe aplastic anaemia and sickle cell anaemia rejected the allogeneic bone marrow transplantation from an HLA-matched unrelated volunteer and an HLA-identical sibling, respectively. In both cases a second transplant using granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) was performed. Donors were the HLA-haploidentical mother and the same HLA-identical sibling who was employed for the first marrow allograft, respectively. Treatment with G-CSF and PBSC collection were well tolerated. Both patients had engraftment of donor haemopoiesis and did not experience severe graft-versus-host disease. These cases confirm that PBSC transplant should be considered as a feasible treatment to reverse graft failure in paediatric patients.
- Published
- 1996
26. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: No differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol
- Author
-
Todeschini, G., primary, Tecchio, C., additional, Degani, D., additional, Meneghini, V., additional, Marradi, P., additional, Balter, R., additional, Zanotti, R., additional, Ricetti, M., additional, Franchini, M., additional, and Perona, G., additional
- Published
- 1997
- Full Text
- View/download PDF
27. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma
- Author
-
Carlo Giussani, Paola Peretta, Daniele Bertin, Piergiorgio Modena, E. Schiavello, Maura Massimino, Ermanno Giombelli, Laura Valentini, Rosalba Miceli, Maria Luisa Garrè, Luna Boschetti, P Bertolini, Giuseppina Calareso, Lorenza Gandola, Salvina Barra, Paolo Ferroli, Barbara Diletto, Giuseppe Cinalli, Veronica Biassoni, Annamaria Buccoliero, Felice Giangaspero, Lucia Quaglietta, Maurizio Mascarin, Angela Mastronuzzi, Milena La Spina, Elisabetta Viscardi, Carlo Efisio Marras, Anna Mussano, Giovanni Scarzello, Armando Cama, Emilia Pecori, Bianca Pollo, Iacopo Sardi, Rita Balter, Francesca R. Buttarelli, Manila Antonelli, Silvia Scoccianti, Lorenzo Genitori, Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, and Gandola, L
- Subjects
Male ,Ependymoma ,Cancer Research ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Neurosurgical Procedures ,surgery ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Prospective cohort study ,Adjuvant ,Etoposide ,grade ,Brain Neoplasms ,boost ,ependymoma ,prognosis ,Chemoradiotherapy ,Chemotherapy regimen ,Treatment Outcome ,Oncology ,Vincristine ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,prognosi ,medicine.drug ,medicine.medical_specialty ,Adolescent ,Cyclophosphamide ,Disease-Free Survival ,03 medical and health sciences ,medicine ,Humans ,Clinical Investigation ,Progression-free survival ,Preschool ,Radiotherapy ,business.industry ,Infant ,Chemoradiotherapy, Adjuvant ,medicine.disease ,Surgery ,Radiation therapy ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
- Published
- 2016
28. EWING SARCOMA OF THE BONE IN CHILDREN UNDER 6 YEARS OF AGE
- Author
-
Antonio Perez Martinez, Maria Antonietta De Ioris, Arcangelo, Prete, Raffaele, Cozza, Marta, Podda, Carla, Manzitti, Andrea, Pession, Elisabetta, Schiavello, Benedetta, Contoli, Rita, Balter, Franca, Fagioli, Bisogno, Gianni, Loredana, Amoroso, Franco, Locatelli, Roberto, Luksch, De Ioris MA, Prete A, Cozza R, Podda M, Manzitti C, Pession A, Schiavello E, Contoli B, Balter R, Fagioli F, Bisogno G, Amoroso L, Locatelli F, and Luksch R.
- Subjects
Male ,Genetics and Molecular Biology (all) ,medicine.medical_treatment ,Cancer Treatment ,lcsh:Medicine ,Kaplan-Meier Estimate ,Pediatrics ,Biochemistry ,Metastasis ,Surgical oncology ,Basic Cancer Research ,Bone and Soft Tissue Sarcomas ,lcsh:Science ,Child ,Multidisciplinary ,Sarcoma ,Combined Modality Therapy ,Oncology ,Italy ,Child, Preschool ,Medicine ,Female ,Research Article ,medicine.medical_specialty ,Ewing Sarcoma ,Bone Neoplasms ,Sarcoma, Ewing ,Disease-Free Survival ,Humans ,Infant ,Proportional Hazards Models ,Biochemistry, Genetics and Molecular Biology (all) ,Agricultural and Biological Sciences (all) ,Ewing ,Internal medicine ,medicine ,Preschool ,Chemotherapy ,PROGNOSTIC-FACTORS, FAMILY TUMORS, IFOSFAMIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE, OSTEOSARCOMA, CHEMOTHERAPY, EXPERIENCE, YOUNGER, IMPACT ,Proportional hazards model ,business.industry ,lcsh:R ,Cancers and Neoplasms ,medicine.disease ,Confidence interval ,Surgery ,Radiation therapy ,Pediatric Oncology ,Localized disease ,lcsh:Q ,business - Abstract
Background Ewing Sarcoma Family Tumours (ESFT) are rare in early childhood. The aim of this study was to report the clinical characteristics and outcome of children under 6 years of age affected by ESFT of the bone in Italy. Methods The records of all the children diagnosed with osseous ESFT in centres members of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) from 1990 to 2008 were reviewed. The Kaplan–Meier method was used for estimating overall and progression-free survival (OS, PFS) curves; multivariate analyses were performed using Cox proportional hazards regression model. Results This study includes 62 patients. An axial primary localization was present in 66% of patients, with the primary site in the chest wall in 34%. Fourteen (23%) patients presented metastatic disease. The 5-year OS and PFS were 73% (95% confidence interval, CI, 58–83%) and 72% (95% CI 57–83%) for patients with localized disease and 38% (95% CI 17–60%) and 21% (95% CI 5–45%) for patients with metastatic disease. Metastatic spread, skull/pelvis/spine primary localization, progression during treatment and no surgery predicted worse survival (P
- Published
- 2013
29. Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.
- Author
-
Caddeo G, Tecchio C, Chinello M, Balter R, Zaccaron A, Vitale V, Pezzella V, Bonetti E, Pillon M, Carraro E, Mussolin L, and Cesaro S
- Abstract
The treatment of pediatric patients with refractory or relapsed anaplastic large cell lymphoma (ALCL) is still a major challenge. In addition to conventional chemotherapy and stem cell transplantation, new therapeutic options such as anti-CD30 drugs and anaplastic lymphoma kinase (ALK) inhibitors have been recently introduced in this setting. Among ALK inhibitors, only the first-generation molecule crizotinib is approved for pediatric use, while second-generation molecules, such as brigatinib, are still under investigation. Here we report the case of a 13-year-old boy diagnosed with stage IV ALCL, refractory to first-line conventional chemotherapy and second-line therapy with the anti CD30 antibody-drug conjugate brentuximab-vedotin, who finally achieved remission after a combination of conventional high-dose chemotherapy and the second-generation ALK inhibitor brigatinib. The latter was chosen for its ability to penetrate through the blood-brain barrier, due to the persistent involvement of the patient's cerebral nervous system. The remission was then consolidated with an allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor using myeloablative conditioning with total body irradiation. At 24 months after HSCT, the patient is in complete remission, alive and well. An updated review regarding the use of ALK inhibitors in ALCL patients is provided., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
30. Characteristics and Outcomes of Bloodstream Infections in a Tertiary-Care Pediatric Hematology-Oncology Unit: A 10-Year Study.
- Author
-
Mattei D, Baretta V, Mazzariol A, Maccacaro L, Balter R, Zaccaron A, Bonetti E, Chinello M, Vitale V, Caddeo G, Esposto MP, Pezzella V, Gibellini D, Tridello G, and Cesaro S
- Abstract
Bloodstream infections (BSIs) after chemotherapy or hematopoietic stem cell transplantation (HSCT) are a leading cause of morbidity and mortality. Data on 154 BSIs that occurred in 111 onco-hematological patients (57 hematological malignancies, 28 solid tumors, and 26 non-malignant hematological diseases) were retrospectively collected and analyzed. Monomicrobial Gram-positive (GP), Gram-negative (GN), and fungal BSIs accounted for 50% (77/154), 38.3% (59/144), and 3.2% (5/154) of all episodes. Polymicrobial infections were 7.8% (12/154), while mixed bacterial-fungal infections were 0.6% (1/154). The most frequent GN isolates were Escherichia coli (46.9%), followed by Pseudomonas aeruginosa (21.9%), Klebsiella species (18.8%), and Enterobacter species (6.3%). Overall, 18.8% (12/64) of GN organisms were multidrug-resistant (seven Escherichia coli , three Klebsiella pneumoniae , and two Enterobacter cloacae ), whereas GP resistance to glycopeptides was observed in 1% (1/97). Initial empirical antibiotic therapy was deemed inappropriate in 12.3% of BSIs (19/154). The 30-day mortality was 7.1% (11/154), while the bacteremia-attributable mortality was 3.9% (6/154). In multivariate analysis, septic shock was significantly associated with 30-day mortality ( p = 0.0001). Attentive analysis of epidemiology and continuous microbiological surveillance are essential for the appropriate treatment of bacterial infections in pediatric onco-hematological patients.
- Published
- 2022
- Full Text
- View/download PDF
31. Long-term and quality of survival in patients treated for acute lymphoblastic leukemia during the pediatric age.
- Author
-
Devilli L, Garonzi C, Balter R, Bonetti E, Chinello M, Zaccaron A, Vitale V, De Bortoli M, Caddeo G, Baretta V, Tridello G, and Cesaro S
- Abstract
Long-term survival for acute lymphoblastic leukemia (ALL) in children improved over the last three decades up to 80-90% of affected patients. Consequently, the quality of life of survivors has become increasingly important. This study analyses the clinical features and outcome of 119 children with ALL, focusing on the quality of long-term survival in a subset of 22 patients over 18 years of age. Among this group, the 10-year event-free survival and overall survival were 83.1% (C.I. 74.0-89.2) and 88.4% (C.I. 80.9-93.1), respectively. Treatment related long-term medical complications were reported only in 2 patients (9.1%). Secondary school was completed successfully in 20 of 22 patients (89.9%). The remaining 2 patients were still attending at the time of the analysis. In conclusion, current treatment for ALL is well tolerated and does not compromise significantly the quality of life of survivors., Competing Interests: Conflict of interest: the authors declare no conflict of interests., (©Copyright: the Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
32. The Diagnostic Pitfalls of Mucormycosis.
- Author
-
Mauro M, Lo Cascio G, Balter R, Zaccaron A, Bonetti E, Vitale V, Chinello M, De Bortoli M, Brazzarola P, Bruno C, and Cesaro S
- Abstract
Background: Invasive mucormycosis is a very aggressive fungal disease among immunocompromised pediatric patients caused by saprophytic fungi that belong to the order of the Mucorales., Case Report: We describe a case of of Lichtheimia corymbifera infection in a 15-year-old child with B-cell-Non-Hodgkin Lymphoma (B-NHL) involving lung, kidney and thyroid that initially was diagnosed as probable aspergillosis delaying the effective therapy for mucormycosis., Conclusions: This case showed that also the intensive chemotherapy for B-NHL may represent a risk factor for mucormycosis infection. Liposomal amphotericin B and surgery remain the key tools for the successful treatment of this aggressive disease., Competing Interests: Competing interests: The authors declare no conflict of Interest.
- Published
- 2020
- Full Text
- View/download PDF
33. Acute Cervical Longitudinally Extensive Transverse Myelitis in a Child With Lipopolysaccharide-Responsive-Beige-Like-Anchor-Protein (LRBA) Deficiency: A New Complication of a Rare Disease.
- Author
-
Chinello M, Mauro M, Cantalupo G, Talenti G, Mariotto S, Balter R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Di Carlo D, Barzaghi F, and Cesaro S
- Abstract
Lipopolysaccharide responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency disorder (PID) that can cause a common variable immunodeficiency (CVID)-like disease. The typical features of the disease are autoimmunity, chronic diarrhea, and hypogammaglobulinemia. Neurological complications are also reported in patients affected by LRBA deficiency. We describe a 7-year old female with an acute cervical longitudinally extensive transverse myelitis (LETM) as a feature of LRBA deficiency. This is the first case of LETM associated with LRBA deficiency described in literature., (Copyright © 2020 Chinello, Mauro, Cantalupo, Talenti, Mariotto, Balter, De Bortoli, Vitale, Zaccaron, Bonetti, Di Carlo, Barzaghi and Cesaro.)
- Published
- 2020
- Full Text
- View/download PDF
34. The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases.
- Author
-
Garonzi C, Balter R, Tridello G, Pegoraro A, Pegoraro M, Pacenti M, Scattolo N, and Cesaro S
- Abstract
Background/aim: The antibody titer of vaccine-preventable diseases in pediatric patients who underwent chemotherapy was assessed in order to evaluate the seroprotection after treatment and the feasibility and the efficacy of a policy of revaccination., Methods: Serum antibody titers of 55 patients for hepatitis B (HBV), rubella, varicella-zoster (VZV), measles, mumps, polio viruses, Clostridium tetani ( C. tetani ) and Streptococcus pneumoniae ( S. pneumoniae ) were analysed.Results: After chemotherapy, a lack of protective antibody titers against HBV, rubella, VZV, measles, mumps, polio viruses, C. tetani , and S. pneumoniae was found in 53%, 45%, 46%, 46%, 43%, 21-26%, 88% and 55% of patients, respectively. In 49 of 55 patients who were tested both before and after chemotherapy for at least a pathogen, the loss of immunity for HBV, rubella, VZV, measles, mumps, polio viruses and C. tetani was respectively 39%, 43%, 38%, 42%, 32%, 33%, and 80%. A low number of B-lymphocytes was associated with the loss of immunity against measles (p=0.04) whereas a high number of CD8+ T-lymphocytes was associated with the loss of immunity against VZV (p=0.03). A single booster of vaccine dose resulted in a seroprotection for HBV, rubella, VZV, measles, mumps, polio viruses, C. tetani and S. pneumoniae in 67%, 83%, 80%, 67%, 33%, 100%, 88% and 67% of patients, respectively., Conclusions: We confirm that seroprotection for vaccine-preventable diseases is affected by treatment for pediatric malignancy. A single booster dose of vaccine might be a practical way to restore vaccine immunity in patients after chemotherapy., Competing Interests: Competing interests: The authors declare no conflict of Interest.
- Published
- 2020
- Full Text
- View/download PDF
35. Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation.
- Author
-
Chinello M, Balter R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Tonin P, Vattemi G, Guglielmi V, and Cesaro S
- Abstract
Background: Chronic graft versus host disease (cGVHD) occurs in 20-30% of paediatric patients receiving haemopoietic stem cell transplantation (HSCT). Neuromuscular disorders such as polymyositis are considered a rare and distinctive but non-diagnostic manifestation of cGVHD and, in the absence of other characteristic signs and symptoms, biopsy is highly recommended to exclude other causes., Case Report: We report a case of a 17-months-old child affected by hemophagocytic lymphohistiocytosis who underwent a matched unrelated donor haematopoietic stem cell transplantation (HSCT). She developed severe cGVHD-related polymyositis that was successfully treated with high-dose steroid therapy, rituximab and sirolimus., Conclusions: This is the first case of cGVHD-related-polymyositis described in a pediatric patient which was successfully treated with rituximab., Competing Interests: Competing interests: The authors declare no conflict of Interest.
- Published
- 2020
- Full Text
- View/download PDF
36. Pure Red Cell Aplasia (PRCA) and Cerebellar Hypoplasia as Atypical Features of Polyglandular Autoimmune Syndrome Type I (APS-1): Two Sisters With the Same AIRE Mutation but Different Phenotypes.
- Author
-
Chinello M, Mauro M, Cantalupo G, Balter R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Gaudino R, Fiorini E, and Cesaro S
- Abstract
The polyglandular autoimmune syndrome type I is a rare hereditary autosomal recessive disease. We describe a child with the classic triad of the disease and her sister with pure red cell aplasia and cerebellar hypoplasia. The latter received two haematopoietic stem cell transplantations, complicated by an acute disseminated encephalomyelitis.
- Published
- 2019
- Full Text
- View/download PDF
37. ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Barzaghi F, Minniti F, Mauro M, Bortoli M, Balter R, Bonetti E, Zaccaron A, Vitale V, Omrani M, Zoccolillo M, Brigida I, Cicalese MP, Degano M, Hershfield MS, Aiuti A, Bondarenko AV, Chinello M, and Cesaro S
- Subjects
- Adenosine Deaminase immunology, Apoptosis drug effects, Apoptosis immunology, Autoimmune Lymphoproliferative Syndrome enzymology, Autoimmune Lymphoproliferative Syndrome immunology, Autoimmune Lymphoproliferative Syndrome pathology, Child, Preschool, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Intercellular Signaling Peptides and Proteins immunology, Neutropenia enzymology, Neutropenia immunology, Neutropenia pathology, Neutropenia therapy, Transplantation, Homologous, fas Receptor immunology, Adenosine Deaminase deficiency, Autoimmune Lymphoproliferative Syndrome therapy, Hematopoietic Stem Cell Transplantation, Intercellular Signaling Peptides and Proteins deficiency, Transplantation Conditioning, Unrelated Donors
- Abstract
Adenosine deaminase 2 (ADA2) deficiency is an auto-inflammatory disease due to mutations in cat eye syndrome chromosome region candidate 1 ( CECR1 ) gene, currently named ADA2 . The disease has a wide clinical spectrum encompassing early-onset vasculopathy (targeting skin, gut and central nervous system), recurrent fever, immunodeficiency and bone marrow dysfunction. Different therapeutic options have been proposed in literature, but only steroids and anti-cytokine monoclonal antibodies (such as tumor necrosis factor inhibitor) proved to be effective. If a suitable donor is available, hematopoietic stem cell transplantation (HSCT) could be curative. Here we describe a case of ADA2 deficiency in a 4-year-old Caucasian girl. The patient was initially classified as autoimmune neutropenia and then she evolved toward an autoimmune lymphoproliferative syndrome (ALPS)-like phenotype. The diagnosis of ALPS became uncertain due to atypical clinical features and normal FAS-induced apoptosis test. She was treated with G-CSF first and subsequently with immunosuppressive drugs without improvement. Only HSCT from a 9/10 HLA-matched unrelated donor, following myeloablative conditioning, completely solved the clinical signs related to ADA2 deficiency. Early diagnosis in cases presenting with hematological manifestations, rather than classical vasculopathy, allows the patients to promptly undergo HSCT and avoid more severe evolution. Finally, in similar cases highly suspicious for genetic disease, it is desirable to obtain molecular diagnosis before performing HSCT, since it can influence the transplant procedure. However, if HSCT has to be performed without delay for clinical indication, related donors should be excluded to avoid the risk of relapse or partial benefit due to a hereditary genetic defect.
- Published
- 2019
- Full Text
- View/download PDF
38. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.
- Author
-
Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, and Haney M
- Subjects
- Adult, Double-Blind Method, Dronabinol pharmacology, Drug Synergism, Female, Humans, Male, Middle Aged, Pain Measurement drug effects, Young Adult, Analgesia, Analgesics, Opioid pharmacology, Marijuana Smoking psychology, Opioid-Related Disorders psychology, Oxycodone pharmacology
- Abstract
Cannabinoids combined with opioids produce synergistic antinociceptive effects, decreasing the lowest effective antinociceptive opioid dose (i.e., opioid-sparing effects) in laboratory animals. Although pain patients report greater analgesia when cannabis is used with opioids, no placebo-controlled studies have assessed the direct effects of opioids combined with cannabis in humans or the impact of the combination on abuse liability. This double-blind, placebo-controlled, within-subject study determined if cannabis enhances the analgesic effects of low dose oxycodone using a validated experimental model of pain and its effects on abuse liability. Healthy cannabis smokers (N = 18) were administered oxycodone (0, 2.5, and 5.0 mg, PO) with smoked cannabis (0.0, 5.6% Δ
9 tetrahydrocannabinol [THC]) and analgesia was assessed using the Cold-Pressor Test (CPT). Participants immersed their hand in cold water (4 °C); times to report pain (pain threshold) and withdraw the hand from the water (pain tolerance) were recorded. Abuse-related effects were measured and effects of oxycodone on cannabis self-administration were determined. Alone, 5.0 mg oxycodone increased pain threshold and tolerance (p ≤ 0.05). Although active cannabis and 2.5 mg oxycodone alone failed to elicit analgesia, combined they increased pain threshold and tolerance (p ≤ 0.05). Oxycodone did not increase subjective ratings associated with cannabis abuse, nor did it increase cannabis self-administration. However, the combination of 2.5 mg oxycodone and active cannabis produced small, yet significant, increases in oxycodone abuse liability (p ≤ 0.05). Cannabis enhances the analgesic effects of sub-threshold oxycodone, suggesting synergy, without increases in cannabis's abuse liability. These findings support future research into the therapeutic use of opioid-cannabinoid combinations for pain.- Published
- 2018
- Full Text
- View/download PDF
39. Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature.
- Author
-
Chinello M, Di Carlo D, Olivieri F, Balter R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Parisi A, and Cesaro S
- Abstract
Background: Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumour of the infancy and the first decade of life. It is locally aggressive and potentially life threatening when associated with consumptive coagulopathy, known as Kasabach-Merritt syndrome (KMS). No consensus or guideline for the therapy has been reached because of the lack of prospective trials, and the different standard care suggestions are based on retrospective case series., Case Report: We report the case of a 9-month-old male with KHE and KMS in which the initial response, obtained with prednisone and vincristine, was subsequently consolidated and strengthened by long-term treatment with sirolimus, a mTOR inhibitor. A summary of the published data is presented as well., Conclusions: The inhibition of mTOR pathway represents the most important therapeutic innovation introduced in the last few years for KHE. Our case shows the effectiveness and good tolerance of long-term therapy with sirolimus., Competing Interests: Competing interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
40. Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report.
- Author
-
Mauro M, Bonetti E, Balter R, Poli G, and Cesaro S
- Abstract
Competing Interests: The Authors declare no conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
41. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.
- Author
-
Massimino M, Miceli R, Giangaspero F, Boschetti L, Modena P, Antonelli M, Ferroli P, Bertin D, Pecori E, Valentini L, Biassoni V, Garrè ML, Schiavello E, Sardi I, Cama A, Viscardi E, Scarzello G, Scoccianti S, Mascarin M, Quaglietta L, Cinalli G, Diletto B, Genitori L, Peretta P, Mussano A, Buccoliero A, Calareso G, Barra S, Mastronuzzi A, Giussani C, Marras CE, Balter R, Bertolini P, Giombelli E, La Spina M, Buttarelli FR, Pollo B, and Gandola L
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms mortality, Brain Neoplasms pathology, Chemoradiotherapy, Adjuvant mortality, Child, Child, Preschool, Cyclophosphamide administration & dosage, Disease-Free Survival, Ependymoma mortality, Ependymoma pathology, Etoposide administration & dosage, Female, Humans, Infant, Kaplan-Meier Estimate, Male, Neurosurgical Procedures mortality, Radiotherapy, Treatment Outcome, Vincristine administration & dosage, Brain Neoplasms therapy, Chemoradiotherapy, Adjuvant methods, Ependymoma therapy, Neurosurgical Procedures methods
- Abstract
Background: This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III)., Methods: WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone., Results: From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable., Conclusions: In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports., (© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
42. The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation.
- Author
-
Mauro M, Camoglio F, Piccoli P, De Bortoli M, Balter R, Pegoraro A, and Cesaro S
- Abstract
In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and splenectomy. We describe here three patients with refractoriness to platelet transfusion due to anti-human leukocyte antibodies who were splenectomized before HSCT (two cases) and after HSCT (one case) due to the lack of efficacy of other therapies. Splenectomy was uneventful. All three patients achieved a full donor engraftment. We suggest that splenectomy is feasible and effective in HSCT patients to reduce the risk of graft failure or delayed engraftment.
- Published
- 2016
- Full Text
- View/download PDF
43. The high oxygen affinity haemoglobin Nantes: a family case description.
- Author
-
Artuso A, Balter R, Bonetti E, Zambon C, Ravani A, Dolcini B, Masieri MT, Salvagno GL, Zanotti R, Pizzolo G, and Veneri D
- Subjects
- Adolescent, Female, Humans, Male, Middle Aged, Hemoglobins, Abnormal genetics, Hemoglobins, Abnormal metabolism, Oxygen metabolism
- Published
- 2015
- Full Text
- View/download PDF
44. Shaped composite liquid marbles.
- Author
-
Bormashenko E, Balter R, Aharoni H, and Aurbach D
- Abstract
Shaped "cubic" non-stick droplets are reported. Shaped composite droplets were manufactured via a two-stage process. In the first stage, cubic foamed-polystyrene particles were hydrophilized with cold radiofrequency plasma. Then particles were wetted with water. In the second stage, they were coated with solid, colloidal particles such as lycopodium, Teflon or carbon black. Thus, "liquid marble"-like non-stick shaped droplets were obtained. The shaped "cubic" droplets remained stable when supported by a NaCl water solution. Shaped Janus droplets coated on one side with dielectric Teflon and with semiconductor carbon black on the other side, were prepared. Janus marbles were actuated with an electric field., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
45. Ewing sarcoma of the bone in children under 6 years of age.
- Author
-
De Ioris MA, Prete A, Cozza R, Podda M, Manzitti C, Pession A, Schiavello E, Contoli B, Balter R, Fagioli F, Bisogno G, Amoroso L, Locatelli F, and Luksch R
- Subjects
- Bone Neoplasms pathology, Bone Neoplasms therapy, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Infant, Italy, Kaplan-Meier Estimate, Male, Proportional Hazards Models, Sarcoma, Ewing pathology, Sarcoma, Ewing therapy, Bone Neoplasms epidemiology, Disease-Free Survival, Sarcoma, Ewing epidemiology
- Abstract
Background: Ewing Sarcoma Family Tumours (ESFT) are rare in early childhood. The aim of this study was to report the clinical characteristics and outcome of children under 6 years of age affected by ESFT of the bone in Italy., Methods: The records of all the children diagnosed with osseous ESFT in centres members of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) from 1990 to 2008 were reviewed. The Kaplan-Meier method was used for estimating overall and progression-free survival (OS, PFS) curves; multivariate analyses were performed using Cox proportional hazards regression model., Results: This study includes 62 patients. An axial primary localization was present in 66% of patients, with the primary site in the chest wall in 34%. Fourteen (23%) patients presented metastatic disease. The 5-year OS and PFS were 73% (95% confidence interval, CI, 58-83%) and 72% (95% CI 57-83%) for patients with localized disease and 38% (95% CI 17-60%) and 21% (95% CI 5-45%) for patients with metastatic disease. Metastatic spread, skull/pelvis/spine primary localization, progression during treatment and no surgery predicted worse survival (P<0.01), while patients treated in the last decade had better survival (P = 0.002). In fact, the 5-year OS and PFS for patients diagnosed in the period 2000-2008 were 89% (95% CI 71-96%) and 86% (95% CI 66-94%), respectively., Conclusion: The axial localization is the most common site of ESFT in pre-scholar children. Patients treated in the most recent period have an excellent outcome.
- Published
- 2013
- Full Text
- View/download PDF
46. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.
- Author
-
Cesaro S, Nesi F, Tridello G, Abate M, Panizzolo IS, Balter R, and Calore E
- Subjects
- Adolescent, Child, Child, Preschool, Filgrastim, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Infant, Male, Neoplasms surgery, Polyethylene Glycols, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Survival Analysis, Transplantation Conditioning methods, Treatment Outcome, Granulocyte Colony-Stimulating Factor therapeutic use, Peripheral Blood Stem Cell Transplantation methods
- Abstract
Purpose: To assess the non-inferiority of pegfilgrastim versus filgrastim in speeding the recovery of polymorphonuclear cells (PMN) in pediatric patients who underwent autologous peripheral blood stem cell transplant (PBSCT)., Methods: The sample size of this randomized, multicenter, phase III study, was calculated assuming that a single dose of pegfilgrastim of 100 ug/kg was not inferior to 9 doses of filgrastim of 5 ug/kg/day. Randomization was performed by a computer-generated list and stored by sequentially numbered sealed envelopes., Results: Sixty-one patients, with a median age of 11.5 years, were recruited: 29 in the filgrastim arm and 32 in the pegfilgrastim arm. Twenty percent were affected by lymphoma/leukaemia and eighty percent by solid tumors. The mean time to PMN engraftment was 10.48 days (standard deviation [SD] 1.57) and 10.44 days (SD 2.44) in the filgrastim and pegfilgrastim arms, respectively. Having fixed a non-inferiority margin Delta of 3, the primary endpoint of non-inferiority was reached. No differences were observed for other secondary endpoints: platelet engraftment, mean time to platelet recovery (28 days vs. 33 days), fever of unknown origin (79% vs. 78%), proven infection (34% vs. 28%), mucositis (76% vs. 59%). After a median follow-up of 2.3 years (95% C.I.: 1.5, 3.3), 20 deaths were observed due to disease progression., Conclusions: We conclude that pegfilgrastim was not inferior to daily filgrastim in pediatric patients who underwent PBSCT. EU CLINICAL TRIAL REGISTER NUMBER: 2007-001430-14.
- Published
- 2013
- Full Text
- View/download PDF
47. Formation of liquid marbles and wetting transitions.
- Author
-
Bormashenko E, Balter R, and Aurbach D
- Abstract
The formation of liquid marbles was studied in the situation where hydrophobic particles coating the marbles "come from air". Droplets of water/ethanol solutions of various concentrations were coated with three kinds of powders: polytetrafluoroethylene, polyvinylidene fluoride and polyethylene. We established that there exists a critical concentration of ethanol, and correspondingly a critical surface tension of the water/ethanol solution allowing formation of liquid marbles. A critical surface tension depends on the kind of the powder. In parallel, wetting transitions of water/ethanol solutions were studied on the layers of the same polymer powders. The onset of wetting transitions on the powders took place at the concentrations of ethanol coinciding with those enabling the formation of liquid marbles. Wetting transitions stipulate the formation of liquid marbles when a droplet is deposited on a layer of hydrophobic powder. This assumption was validated by the experiments performed with di-iodomethane and glycerol., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
48. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
- Author
-
Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, and Pizzolo G
- Subjects
- Adolescent, Adult, Aged, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Burkitt Lymphoma pathology, Child, Child, Preschool, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Staging, Remission Induction, Rituximab, Time Factors, Transplantation, Homologous, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Burkitt Lymphoma drug therapy, Burkitt Lymphoma mortality
- Abstract
The optimal treatment of advanced sporadic Burkitt lymphoma in adults is still a matter of debate. The salutary results of pediatric therapies did open the road for improving the adult outcome. Between May 1988 and March 2009, 71 consecutive patients-46 adults, 25 children-affected by Burkitt lymphoma/leukemia were treated with the same intensive pediatric protocol alternating vincristine, adriamycine and fractionated ciclophosphamide (phase A) with high dose methotrexate and high dose cytarabine (phase B) in four Italian institutions. Eighty-nine per cent of patients were in Stage III-IV or had L3 leukemia. Complete remissions were 67/71 (94.4%), 24/25 (96%) in children, and 43/46 (93.5%) in adults. Toxic deaths were 3/71 (4.2%), all in adults. There were nine relapses (one in children, eight in adults), all but one observed early. After a median observation of 94 months (range 23-275), the Event-Free Survival rate is 92% in children and 71.7% in adults (P = 0.067). The 23 more recent adults received also rituximab, without differences in outcome as compared to patients who did not. Our experience confirms that such an intensive pediatric-derived chemotherapy is feasible and improves the long-term outcome of adults with advanced Burkitt lymphoma., (Copyright © 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.